NCT02489006 2024-01-17
NEO
University Health Network, Toronto
Phase 2 Unknown
Clinical Trials
33 trialsNCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT04375267 2023-11-14
LuPARP
Vastra Gotaland Region
Phase 1 Unknown
NCT02229656 2023-11-07
Olaparib and Radiotherapy in Head and Neck Cancer
The Netherlands Cancer Institute
Phase 1 Unknown
NCT04091204 2023-03-24
MITO 31
National Cancer Institute, Naples
Phase 2 Unknown
NCT05201612 2023-02-24
PEMBROLA
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Unknown
NCT05167175 2022-10-25
The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT03278717 2022-09-27
ICON9
University College, London
Phase 3 Unknown
NCT04015739 2022-08-17
BOLD
ARCAGY/ GINECO GROUP
Phase 2 Unknown
NCT04641728 2022-08-09
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT05440578 2022-07-01
First-line Olaparib Combined With Bevacizumab Maintenance Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT05262608 2022-03-02
PROspect
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT05245994 2022-02-18
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Phase 2 Unknown
NCT02446704 2022-02-07
Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Massachusetts General Hospital
Phase 1/2 Unknown
NCT05081765 2021-10-18
The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib
Poznan University of Medical Sciences
Unknown
NCT05044091 2021-09-14
HOPEI
Jiangsu Cancer Institute & Hospital
Unknown
NCT03951415 2021-04-01
DOMEC
Leiden University Medical Center
Phase 2 Unknown
NCT02822157 2021-01-29
CLIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Unknown
NCT04582552 2021-01-20
ROMP
Jiangsu Cancer Institute & Hospital
Unknown
NCT04566952 2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04261465 2020-02-07
NUVOLA
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT03829345 2019-07-08
SOLAR
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT03925233 2019-04-24
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Unknown
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT01788332 2018-10-26
PIN
Velindre NHS Trust
Phase 2 Unknown
NCT01650376 2018-03-23
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Swedish Medical Center
Phase 1/2 Unknown
NCT02679963 2017-08-01
PIPSeN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT02684318 2017-06-22
Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
Poveda, Andrés, M.D.
Phase 1/2 Unknown
NCT02681562 2016-02-15
Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients
Istituti Ospitalieri di Cremona
Phase 2 Unknown
NCT01460888 2013-08-19
ROCOCO
The Christie NHS Foundation Trust
Phase 1 Unknown